TNF and Crohn disease: Data from Ontario and Manitoba have also shown increasing penetration of anti-TNF therapy in persons with Crohn’s disease over the first decade following market introduction, but very little uptake in individuals with ulcerative colitis; this suggests that underuse of biologic therapies may limit the population-level impact on ulcerative colitis disease course (11, 12).